Precision BioSciences, Inc. (DTIL)
| Market Cap | 196.48M +261.6% |
| Revenue (ttm) | 45.07M -11.9% |
| Net Income | -43.60M |
| EPS | -2.62 |
| Shares Out | 25.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 481,656 |
| Open | 7.35 |
| Previous Close | 7.23 |
| Day's Range | 7.06 - 7.85 |
| 52-Week Range | 3.53 - 8.82 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 32.00 (+320.22%) |
| Earnings Date | May 5, 2026 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price target is $32.0, which is an increase of 320.22% from the latest price.
News
Precision BioSciences Transcript: AGM 2026
The meeting highlighted progress in gene editing programs, strong financial positioning, and approval of all six proposals, including director elections and governance amendments. No questions were raised by shareholders, and final voting results will be published in a Form 8-K.
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces results from low-dose cohort of ECUR-506
iECURE announced positive results from a preliminary analysis of the completed low-dose cohort of ECUR-506 from the ongoing OTC-HOPE clinical trial in neonatal-onset ornithine transcarbamylase, OTC, d...
Precision BioSciences presents new preclinical data on Pbgene-DMD program
Precision BioSciences (DTIL) announced new preclinical data from its Pbgene-DMD program in an oral presentation at the American Society of Gene & Cell Therapy, ASGCT, 2026 Annual Meeting in Boston,…
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Earnings release: Q1 2026
Precision BioSciences released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Precision BioSciences Quarterly report: Q1 2026
Precision BioSciences has published its Q1 2026 quarterly earnings report on May 5, 2026.
Precision BioSciences sees cash runway through 2028
As of March 31, 2026, Precision had approximately $125.8 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, continued fiscal and opera...
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year
Reports Q1 revenue $10.8M, consensus $4.05M. “During the first quarter, we continued to execute on our two clinical stage in vivo gene editing programs. We advanced PBGENE-HBV into new cohorts…
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences activates first clinical trial site for PBGENE-DMD
Precision BioSciences (DTIL) announced the activation of the first clinical trial site and the opening of patient screening and enrollment for PBGENE-DMD. PBGENE-DMD, the first-in-class in vivo gene e...
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces oral presentation at ASGCT 2026
Precision BioSciences (DTIL) announced that new preclinical data from its PBGENE-DMD program have been accepted for an oral presentation at the American Society of Gene & Cell Therapy, ASGCT, 2026…
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces grant of inducement awards
Precision BioSciences (DTIL) Board of Directors approved the grant of an inducement award of 7,094 restricted stock units to a new employee under the Precision BioSciences, Inc. 2021 Employment Induce...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences assumed with a Buy at JonesResearch
JonesResearch assumed coverage of Precision BioSciences (DTIL) with a Buy rating and $30 price target The firm views the company as an “underappreciated gene editing story.” The price target is…
Precision BioSciences receives CTA approval to expand Eliminate-B trial
Precision BioSciences (DTIL) announced that it has received Clinical Trial Application, CTA, approval to expand the ongoing global Eliminate-B clinical trial of PBGENE-HBV. The regulatory authorizatio...
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: 25th Annual Needham Virtual Healthcare Conference
ARCUS gene editing platform underpins two lead programs: PBGENE-HBV for hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy. Early clinical and preclinical data show promising efficacy and safety, with key data readouts expected in 2026 and a strong cash runway through 2028.
Precision BioSciences Proxy statement: Proxy filing
Precision BioSciences filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Precision BioSciences Proxy statement: Proxy filing
Precision BioSciences filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...